BIIB - Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days (Transcript)
2024-03-19 14:16:03 ET
Biogen Inc. (BIIB)
Stifel 2024 Virtual CNS Days Conference
March 19, 2024 10:00 AM ET
Company Participants
Priya Singhal - Head of Development & Interim Chief Medical Officer
Conference Call Participants
Paul Matteis - Stifel
Presentation
Operator
Paul Matteis
Great. Thank you. Good morning, everybody. It's my pleasure to be hosting this panel with Priya Singhal, Head of Development; and now also Interim Chief Medical Officer at Biogen. Priya has done this panel with me a couple of years in a row, and there's always a lot to talk about. So we really appreciate your time, Priya. Thank you again.
Question-and-Answer Session
Q - Paul Matteis
Maybe just to kind of kick things off, it would be great if you could just give like a 10,000 foot view of the Biogen pipeline, things have been sort of reshaped, right, with the leadership change at the company over the past, say, 1.5 years. And I guess maybe on a forward-looking basis, how satisfied are you with where you're at? And what areas or technologies are you looking to kind of increase your exposure to as things continue to unfold?
Priya Singhal
Sure. Thank you, Paul for having me, and happy to be here. So before we begin, I just wanted to point out that I'm going to be making forward-looking statements. These are based on our current expectations and beliefs and they are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors that are in our SEC filings for additional details.
I believe that we've made significant progress over the last year bringing about kind of a new Biogen as we prioritize our pipeline to invest really where we believe we can deliver the greatest return and enhance value. We've also completed the Reata acquisition, and we realigned the company's structure and overall cost basis to support the best future growth....
Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days (Transcript)